24/7 Market News- It’s Not Synthetic, It’s Real. Kraig Labs Nears Spider Silk Breakthrough
One Million Transgenic Silkworms Being Deployed as Production Targets 10 Metric Tons per Month
DENVER, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the undisputed global leader in the development and commercialization of spider silk, is entering what may prove to be the defining phase of its multi-decade development arc, as the company accelerates toward commercial-scale production of biodegradable spider silk derived from transgenic silkworms.
247 Market News has followed the company’s development since its early scientific milestones, including when Kraig Labs stood before members of the media at a press conference held at the University of Notre Dame, announcing that spider DNA had been successfully integrated into silkworms to produce recombinant spider silk fibers exhibiting strength comparable to native spider silk. Importantly, the company confirmed that the engineered traits were stably integrated and persisted after breeding, demonstrating germline transmission of the spider silk genes.
Shortly thereafter, the Proceedings of the National Academy of Sciences (PNAS) published peer-reviewed findings validating the platform (Proc. Natl. Acad. Sci. U.S.A., DOI: 10.1073/pnas.1109420109). The study confirmed that transgenic silkworms producing composite silk fibers containing stably integrated spider silk protein sequences generated fibers that were, on average, tougher than conventional silkworm silk and comparable in toughness to native dragline spider silk.
Those validations placed Kraig Labs on a path toward industrial scalability. Today, the company operates three production facilities in Vietnam and surrounding provinces and is preparing coordinated deployment of approximately one million proprietary spider silk silkworm eggs across its production network. Beginning in March, the company expects that combined output from the three facilities could support production targeting up to 10 metric tons of recombinant spider silk cocoons per month.
In parallel, Kraig has announced it is building inventory and preparing to fulfill three orders from nationally recognized global brands. According to recent company disclosures, initial shipments are expected once material preparation is completed.
Kraig Labs Is Positioned to Make History
Kraig’s spider silk producing silkworms represent a uniquely rare category in biotechnology. They are the only known transgenic animals whose native biological process directly produces a finished structural material intended for commercial use. Unlike transgenic animal systems developed for pharmaceutical proteins which require extensive purification and downstream processing Kraig’s engineered silkworms spin recombinant spider silk fiber as part of their natural physiology.
As production ramps, these silkworms may become the only transgenic animals currently generating revenue from a biologically assembled structural material at industrial scale.
(KBLB) now has the potential to become only the second company in history to achieve commercial-scale output from a transgenic animal platform, and the first to do so with a naturally spun, biodegradable structural fiber.
The Only Historical Precedent
To understand the magnitude of that milestone, consider the only confirmed commercial precedent in transgenic animal biotechnology.
The commercialization of ATryn required more than two decades of scientific persistence. The concept of using transgenic goats to produce human antithrombin protein in milk began in the mid-1980s, with successful genetic engineering achieved in the early 1990s. What followed was an extended period of breeding stable lines, conducting clinical trials, and navigating regulatory review, a development arc spanning roughly 20 to 25 years.
ATryn ultimately received European approval in 2006 and U.S. FDA approval in 2009. The therapeutic protein was harvested from goat milk, purified, and processed into an injectable drug used to treat hereditary antithrombin deficiency.
The achievement was significant enough that Sanofi acquired Genzyme for $20.1 billion in 2011, incorporating ATryn into its rare disease portfolio.
To date, that remains the only sustained commercial success of transgenic animal biotechnology underscoring the rarity of the milestone Kraig Labs now approaches.
Transformative Fibers Take Time
Breakthrough structural fibers historically require long development and adoption cycles before reaching meaningful commercial scale.
DuPont discovered Kevlar in 1965, yet it took approximately 15 years before the material achieved widespread commercial recognition and large-scale adoption, particularly after its integration into ballistic protection and high-performance industrial applications in the late 1970s and early 1980s.
Even earlier, nylon was discovered in 1935 but required years of refinement, scaling, and manufacturing development before broad commercial deployment.
High-performance fibers must pass through extensive phases of mechanical validation, processing optimization, and industrial qualification before market acceptance occurs. Viewed against this historical timeline, Kraig Labs’ multi-year development path now transitioning toward coordinated production ramp and commercial delivery aligns with the traditional maturation curve of transformative fiber technologies.
A Convergence of Genetics, Biology, and Industrial Execution
What distinguishes Kraig Labs is not simply that it is developing a new fiber, but that it is engineering an entirely new category of biological manufacturing. The company is working with live transgenic animals, utilizing advanced CRISPR-like gene editing techniques to create stable, heritable genetic traits, and translating those traits into a biodegradable structural material with performance characteristics historically associated with synthetic super fibers.
This requires expertise across molecular genetics, breeding science, industrial rearing, materials processing, and supply chain execution disciplines that rarely intersect within a single platform.
If commercial production proceeds as outlined, Kraig will not just be introducing a new fiber to market; it will be demonstrating that complex genetic engineering, when paired with disciplined manufacturing, can produce scalable, revenue-generating biological materials.
Awaiting Brand Disclosure: Expectations Build into Spring
While production infrastructure ramps and inventory builds, investor attention is increasingly focused on the company’s previously disclosed brand engagements. Kraig Labs has indicated that it is working with three nationally recognized global brands, including a high-end luxury fashion house, a leading performance sportswear company, and a top-tier athletic equipment manufacturer. Although specific names have not yet been publicly revealed, management has stated that initial deliveries are expected as material preparation is completed.
As the spring production cycle begins and the coordinated deployment of one million transgenic silkworms moves into full execution, expectations are building around potential confirmation of first commercial shipments and brand identification. The coming weeks may represent a defining period, as operational milestones, customer validation, and production scale converge. For investors, the significance lies not only in volume output, but in the potential transition from confidential pilot collaboration to publicly confirmed commercial relationships.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information, please visit: www.kraiglabs.com
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
